Related Experiment Videos
Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy
Steven G Terra1, Karen K Hamilton, Daniel F Pauly
1Department of Pharmacy Practice, University of Florida College of Pharmacy, Gainesville, FL 32610, USA.
Pharmacogenetics and Genomics
|May 3, 2005
Summary
Heart failure patients with specific beta1-adrenergic receptor gene variants, Arg389Arg and Gly49, show greater left ventricular reverse remodeling and improved ejection fraction with beta-blocker therapy.
Area of Science:
- Cardiology
- Pharmacogenomics
- Genetics
Background:
- Beta-blocker treatment efficacy in heart failure varies significantly.
- Genetic variations in the beta1-adrenergic receptor gene may influence treatment response.
Purpose of the Study:
- To investigate the association between beta1-adrenergic receptor gene polymorphisms (codon 389 Arg389Gly and codon 49 Ser49Gly) and left ventricular (LV) reverse remodeling in heart failure patients undergoing beta-blocker therapy.
Main Methods:
- Prospective enrollment of 61 beta-blocker naive systolic heart failure patients.
- Baseline and follow-up echocardiography after 3 months of metoprolol CR/XL treatment.
- Genotyping for beta1-adrenergic receptor polymorphisms at codons 389 and 49.
Main Results:
- The Arg389Arg genotype was associated with a significant increase in ejection fraction (EF) (23% to 29%, P=0.008).
- Gly389 carriers showed no significant EF change (P=0.45).
- The Arg389Arg genotype and Gly49 variant were linked to greater reductions in LV dimensions and improved EF response.
Conclusions:
- The Arg389Arg genotype and Gly49 variant of the beta1-adrenergic receptor gene are associated with enhanced left ventricular reverse remodeling in response to beta-blocker therapy for heart failure.
- These findings suggest a pharmacogenomic approach to optimizing beta-blocker treatment in heart failure.